EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Long-Term Healthcare Resource Utilization and Costs among Patients with Myasthenia Gravis: A Swedish Nationwide Population-Based Study

Qian Cai, Alberto E Batista, Jakob Börsum, Qiaoyi Zhang, Gabriel Isheden, Peter Kunovszki, Kavita Gandhi, Kristin Heerlein, Susanna Brauner

Neuroepidemiology · 2024

DOI: 10.1159/000538640 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Neuroepidemiology, 2024. Verfasst von Qian Cai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Janssen Global Services, Titusville, New Jersey, USA. Hauptthemen laut MEDLINE: Myasthenia Gravis, Health Care Costs, Patient Acceptance of Health Care. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Healthcare costs and societal impact of myasthenia gravis (MG), a potentially life-threatening rare, chronic neuromuscular disease, are sparsely studied. We assessed healthcare resource utilization (HCRU) and associated costs among patients with newly diagnosed (ND) and preexisting (PE) MG in Sweden.

Methods

This observational, retrospective cohort study used data from four linkable Swedish nationwide population-based registries. Adult MG patients receiving pharmacological treatment for MG and having ≥24-month follow-up during the period January 1, 2010, to December 31, 2017, were included.

Results

A total of 1,275 patients were included in the analysis, of which 554 patients were categorized into the ND MG group and 721 into the PE MG group. Mean (±SD) age was 61.3 (±17.4) years, and 52.3% were female. In the first year post-diagnosis, ND patients had significantly higher utilization of acetylcholinesterase inhibitors (96.0% vs. 83.9%), corticosteroids (59.6% vs. 45.8%), thymectomy (12.1% vs. 0.7%), and plasma exchange (3.8% vs. 0.6%); had higher all-cause (70.9% vs. 35.8%) and MG-related (62.5% vs. 18.4%) hospitalization rates with 11 more hospitalization days (all p < 0.01) and an increased risk of hospitalization (odds ratio [95% CI] = 4.4 [3.43, 5.64]) than PE MG. In year 1 post-diagnosis, ND MG patients incurred EUR 7,302 (p < 0.01) higher total all-cause costs than PE MG, of which 84% were estimated to be MG-related and the majority (86%) were related to inpatient care. These results remained significant also after controlling for baseline demographics and comorbidities (p < 0.01). In year 2 post-diagnosis, the all-cause medical costs decreased by ∼55% for ND MG from year 1 and were comparable with PE MG.

Conclusion

In this population-based study, MG patients required significantly more healthcare resources in year 1 post-diagnosis than PE MG primarily due to more pharmacological treatments, thymectomies, and associated hospitalizations. These findings highlight the need to better understand potential factors including disease characteristics associated with increased health resource use and costs and need for more efficacious treatments early in the disease course.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenia GravisHealth Care CostsPatient Acceptance of Health CareHumansFemaleMaleSwedenMiddle AgedAgedRetrospective StudiesAdultRegistriesHealth ResourcesAged, 80 and overHospitalization

Stichwörter der Autor:innen

Healthcare costsMyasthenia gravisResource utilizationSickness absence

Autor:innen und Institutionen

  • Janssen Global Services, Titusville, New Jersey, USA.
  • SDS Life Science AB, Uppsala, Sweden.
  • Janssen Global Services, Budapest, Hungary.
  • Janssen Global Services, Neuss, Germany.
  • Department of Clinical Neuroscience, Karolinska Institute and Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.

Zitieren

APA

Cai, Q., Batista, A. E., Börsum, J., Zhang, Q., Isheden, G., Kunovszki, P., Gandhi, K., Heerlein, K., & Brauner, S. (2024). Long-Term Healthcare Resource Utilization and Costs among Patients with Myasthenia Gravis: A Swedish Nationwide Population-Based Study. Neuroepidemiology. https://doi.org/10.1159/000538640

Vancouver

Cai Q, Batista AE, Börsum J, Zhang Q, Isheden G, Kunovszki P, et al. Long-Term Healthcare Resource Utilization and Costs among Patients with Myasthenia Gravis: A Swedish Nationwide Population-Based Study. Neuroepidemiology. 2024. doi:10.1159/000538640

BibTeX
@article{Cai2024,
  author = {Cai, Qian and Batista, Alberto E and Börsum, Jakob and Zhang, Qiaoyi and Isheden, Gabriel and Kunovszki, Peter and Gandhi, Kavita and Heerlein, Kristin and Brauner, Susanna},
  title = {Long-Term Healthcare Resource Utilization and Costs among Patients with Myasthenia Gravis: A Swedish Nationwide Population-Based Study},
  journal = {Neuroepidemiology},
  year = {2024},
  doi = {10.1159/000538640}
}
Kostenlos starten →